Clinical trial
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or…
NCT00052442 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00052442 |
|---|---|
| Title | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma |
| Official title | A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Collaborators | National Cancer Institute (NCI) NIH Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | pralatrexate |
| Enrollment | 72 |
| Start date | Aug 1, 2002 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 25, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: